Last reviewed · How we verify
Individualized pharmacokinetically driven paclitaxel dosing
Individualized pharmacokinetically driven paclitaxel dosing optimizes chemotherapy exposure by adjusting paclitaxel doses based on each patient's real-time drug clearance and pharmacokinetic parameters.
Individualized pharmacokinetically driven paclitaxel dosing optimizes chemotherapy exposure by adjusting paclitaxel doses based on each patient's real-time drug clearance and pharmacokinetic parameters. Used for Various solid tumors (paclitaxel-responsive cancers including ovarian, breast, and lung cancers).
At a glance
| Generic name | Individualized pharmacokinetically driven paclitaxel dosing |
|---|---|
| Sponsor | Central European Society for Anticancer Drug Research |
| Drug class | Taxane (paclitaxel) with pharmacokinetically guided dosing |
| Target | Microtubule stabilizer (paclitaxel binds β-tubulin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This approach uses therapeutic drug monitoring and pharmacokinetic modeling to personalize paclitaxel dosing, aiming to achieve target drug exposure while minimizing toxicity. Rather than using fixed body surface area-based dosing, this strategy calculates individual clearance rates and adjusts subsequent doses to maintain optimal plasma concentrations, potentially improving efficacy and tolerability.
Approved indications
- Various solid tumors (paclitaxel-responsive cancers including ovarian, breast, and lung cancers)
Common side effects
- Peripheral neuropathy
- Neutropenia
- Anemia
- Hypersensitivity reactions
- Myalgia/arthralgia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: